Understand the source comparison
Peptides for Male Infertility: Protocol Comparison
Below is a structured comparison of peptides used in male infertility research protocols, including mechanisms, dosing strategies, evidence quality, and practical implementation considerations. Thymosin alpha-1 Nrf2 activation → antioxidant enzyme upregulation
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Below is a structured comparison of peptides used in male infertility research protocols, including mechanisms, dosing strategies, evidence quality, and practical implementation considerations.
- Thymosin alpha-1
- Nrf2 activation → antioxidant enzyme upregulation
- 1.6mg subcutaneously 2× weekly for 12 weeks
- Moderate. RCT with 84 participants, positive outcomes on sperm motility and DNA fragmentation
- Requires consistent twice-weekly dosing; response time 8–12 weeks
- Best suited for cases with elevated oxidative stress markers or high DNA fragmentation index
- Thymalin
- Immune modulation, testicular tissue regeneration
- 10mg intramuscularly daily for 10 days, cycled monthly
- Low to Moderate. Eastern European trials, limited Western replication
- Short high-dose cycles followed by rest periods; regenerative effects may take 2–3 cycles
- Indicated for chronic prostatitis, autoimmune-mediated infertility, or testicular atrophy
- MK 677 (Ibutamoren)
- IGF-1 elevation → mitochondrial biogenesis, Leydig cell support
- 15–25mg orally once daily for 12–16 weeks
- Moderate. Multiple studies on IGF-1 elevation; direct fertility data limited but mechanistically sound
- Oral administration simplifies protocol; monitor fasting glucose and insulin sensitivity
- Best for men with baseline IGF-1 deficiency or metabolic syndrome contributing to infertility
- Cerebrolysin
- HPG axis modulation, neuroprotection of GnRH neurons
- 5–10mL intramuscularly or intravenously 3× weekly for 8 weeks
- Low. Preclinical animal data, case reports in humans
- Requires parenteral administration; neurotropic effects may benefit secondary hypogonadism cases
- Exploratory use in men with central hypogonadism or age-related decline in LH pulsatility
- Dihexa
- HGF/c-Met pathway activation, potential neurogenic and angiogenic effects
- 1–5mg orally or subcutaneously daily for 8–12 weeks (research dosing varies)
- Very Low. Primarily cognitive and neuroprotective research; fertility applications theoretical
- Emerging compound; mechanism suggests potential for testicular microvascular health
- Speculative application; may support tissue repair in cases of testicular ischemia or injury